A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.


Journal

PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 10 2 2019
medline: 2 5 2020
entrez: 10 2 2019
Statut: ppublish

Résumé

The nature of model-based cost-effectiveness analysis can lead to disputes in the scientific community. We propose an iterative and collaborative approach to model development by presenting a flexible open-source simulation model for rheumatoid arthritis (RA), accessible to both technical and non-technical end-users. The RA model is a discrete-time individual patient simulation with 6-month cycles. Model input parameters were estimated based on currently available evidence and treatment effects were obtained with Bayesian network meta-analysis techniques. The model contains 384 possible model structures informed by previously published models. The model consists of the following components: (i) modifiable R and C++ source code available in a GitHub repository; (ii) an R package to run the model for custom analyses; (iii) detailed model documentation; (iv) a web-based user interface for full control over the model without the need to be well-versed in the programming languages; and (v) a general audience web-application allowing those who are not experts in modeling or health economics to interact with the model and contribute to value assessment discussions. A primary function of the initial version of RA model is to help understand and quantify the impact of parameter uncertainty (with probabilistic sensitivity analysis), structural uncertainty (with multiple competing model structures), the decision framework (cost-effectiveness analysis or multi-criteria decision analysis), and perspective (healthcare or limited societal) on estimates of value. In order for a decision model to remain relevant over time it needs to evolve along with its supporting body of clinical evidence and scientific insight. Multiple clinical and methodological experts can modify or contribute to the RA model at any time due to its open-source nature.

Identifiants

pubmed: 30737711
doi: 10.1007/s40273-018-00765-2
pii: 10.1007/s40273-018-00765-2
doi:

Substances chimiques

Biological Products 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

829-843

Références

Rheumatology (Oxford). 2004 Jan;43(1):62-72
pubmed: 12890861
Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv10-8
pubmed: 21859700
Curr Med Res Opin. 2010 Jan;26(1):77-90
pubmed: 19908947
Rheumatol Int. 2015 Sep;35(9):1489-95
pubmed: 25794569
J Manag Care Spec Pharm. 2016 Sep;22(9):1088-102
pubmed: 27579831
J Rheumatol. 2012 Jan;39(1):54-9
pubmed: 22089466
Pharmacoeconomics. 2017 Jan;35(1):125-128
pubmed: 27928759
Arthritis Rheum. 2003 Jun;48(6):1530-42
pubmed: 12794820
Stat Methods Med Res. 2015 Dec;24(6):615-34
pubmed: 21930515
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8
pubmed: 16273793
Arthritis Rheum. 2005 Sep;52(9):2625-36
pubmed: 16142705
Ann Intern Med. 2018 Apr 3;168(7):529
pubmed: 29610903
Arthritis Rheum. 2007 Nov;56(11):3583-7
pubmed: 17968923
Semin Arthritis Rheum. 2014 Oct;44(2):131-44
pubmed: 24925692
Rheumatology (Oxford). 2013 May;52(5):944-50
pubmed: 23339232
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794
pubmed: 21328309
Med Decis Making. 2017 Oct;37(7):735-746
pubmed: 28061043
Natl Vital Stat Rep. 2015 Sep 22;64(11):1-63
pubmed: 26460931
Rheumatology (Oxford). 2003 Feb;42(2):244-57
pubmed: 12595618
Arthritis Care Res (Hoboken). 2011 Mar;63(3):366-72
pubmed: 21080449
Ann Rheum Dis. 2017 Jun;76(6):1101-1136
pubmed: 28298374
Arthritis Rheum. 2008 Apr;58(4):939-46
pubmed: 18383356
Arthritis Res Ther. 2005;7(4):R796-806
pubmed: 15987481
Arthritis Res Ther. 2010;12(2):R35
pubmed: 20196859
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Stat Med. 2016 Oct 15;35(23):4264-80
pubmed: 27189534
Value Health. 2016 Jan;19(1):1-13
pubmed: 26797229
Value Health. 2015 Mar;18(2):173-9
pubmed: 25773552
J R Stat Soc Ser C Appl Stat. 2010 Mar;59(2):233-253
pubmed: 20383261
Pharmacoeconomics. 2016 Apr;34(4):349-61
pubmed: 26660529
Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1
pubmed: 20674669
Clin Exp Rheumatol. 2013 May-Jun;31(3):334-40
pubmed: 23324808
Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv26-31
pubmed: 21859702
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25
pubmed: 26545825
Arthritis Care Res (Hoboken). 2010 Mar;62(3):362-70
pubmed: 20391482
BMJ Open. 2015 Jun 09;5(6):e006560
pubmed: 26059521
Health Econ. 2005 Apr;14(4):339-47
pubmed: 15736142
Arthritis Care Res (Hoboken). 2011 Dec;63(12):1672-9
pubmed: 21954144
Arthritis Care Res (Hoboken). 2012 May;64(5):640-7
pubmed: 22473918
J Rheumatol. 2017 Jul;44(7):973-980
pubmed: 28202743
Stud Health Technol Inform. 2016;226:115-8
pubmed: 27350481
Med Decis Making. 2013 Oct;33(7):880-90
pubmed: 23811758
Eur J Health Econ. 2008 Jan;8 Suppl 2:S49-60
pubmed: 18157732
Health Technol Assess. 2016 Apr;20(35):1-610
pubmed: 27140438
Eur J Health Econ. 2013 Apr;14(2):197-209
pubmed: 22057665
Arthritis Rheum. 2008 Jan;58(1):15-25
pubmed: 18163481
Pharmacoeconomics. 2014 Aug;32(8):775-87
pubmed: 24854959
Value Health. 2017 Feb;20(2):213-216
pubmed: 28237197

Auteurs

Devin Incerti (D)

Innovation and Value Initiative, 11100 Santa Monica Boulevard, Suite 500, Los Angeles, CA, 90025, USA.

Jeffrey R Curtis (JR)

Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.

Jason Shafrin (J)

Innovation and Value Initiative, 11100 Santa Monica Boulevard, Suite 500, Los Angeles, CA, 90025, USA.

Darius N Lakdawalla (DN)

Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.

Jeroen P Jansen (JP)

Innovation and Value Initiative, 11100 Santa Monica Boulevard, Suite 500, Los Angeles, CA, 90025, USA. jeroen.jansen@thevalueinitiative.org.
Department of Health Research and Policy (Epidemiology), Stanford University School of Medicine, Stanford, CA, USA. jeroen.jansen@thevalueinitiative.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH